Amyotrophic lateral sclerosis (ALS) belongs to a group of neurological disease. Otherwise called motor neuron diseases, they influence the engine elements of voluntary muscles in the body. Factors, for example, an expansion in the occurrence rate of ALS, grow in the awareness about the ailment among patients, and ascend in the geriatric populace is relied upon to help the development of the amyotrophic lateral sclerosis market. Other factors including the tendency towards the stationary way of life are driving the market development and expanding the danger of getting attacked by ALS. Furthermore, the expanding geriatric populace substantiates market development, making interest in symptomatic and focused on treatment alternatives. However, the staggering expense of the treatment of ALS may impede market development over the figure time frame. The market is growing at 7.89 % CAGR and is expected to reach the valuation of USD 841.6 million by the year 2023.
Download Free Sample Pages of this report
The Global amyotrophic lateral sclerosis market has been classified on the basis of its treatment, type, end-user, and regional demand. Based on its type, the market is classified into familial ALS and sporadic. On the basis of its treatment, the market has been segmented into physical therapy, speech therapy, medication, respiratory therapy, and others. By its end-user, the ALS market has been segmented into research & academic institutes, specialty centers, hospitals, and others.
Geographically, the Global amyotrophic lateral sclerosis market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada), Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), among others are some of the major players in the Global amyotrophic lateral sclerosis market.